Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 3/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | CD38 | P28907 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL28701148 | 0.85 | KDM1A (0.40) | KDM1AHTR4ACKR3CARM1PRMT6 | |
| SCHEMBL963156 | 0.84 | KDM1A (0.49) | KDM1AHTR4ACKR3CARM1PRMT6 | |
| SCHEMBL25389091 | 0.77 | KDM1A (0.47) | KDM1AHTR4ACKR3CARM1PRMT6 | |
| Trifluoroacetic Acid SCHEMBL2356674 | 0.76 | MEN1 (0.52) | HSD11B1SMN1; SMN2 | |
| SCHEMBL5949639 | 0.75 | HRH2 (0.46) | KDM1AHTR4ACKR3LTA4HHRH4 | |
| SCHEMBL4547144 | 0.75 | KDM1A (0.50) | KDM1AHTR4ACKR3CARM1PRMT6 | |
| SCHEMBL18551217 | 0.75 | HRH2 (0.46) | KDM1AHTR4ACKR3LTA4HHRH4 | |
| SCHEMBL12332732 | 0.74 | LTA4H (0.54) | KDM1AHTR4ACKR3CARM1PRMT6 | |
| Hydrochloric Acid SCHEMBL6496133 | 0.73 | HRH2 (0.45) | KDM1AHTR4ACKR3LTA4HHRH4 | |
| SCHEMBL18551063 | 0.73 | KDM1A (0.48) | KDM1AHTR4ACKR3CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2022-06-07 | — | — | US | disclosed |
| CN-108707139-B | Aminopyrimidine compound and preparation method and application thereof | 北京鞍石生物科技有限责任公司 | 2021-04-06 | — | — | CN | disclosed |
| EP-3640248-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-04-22 | — | — | EP | disclosed |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-03-19 | — | — | US | disclosed |
| CN-108707139-A | Amino-metadiazine compound and its preparation method and application | 北京浦润奥生物科技有限责任公司 | 2018-10-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, EGFR | KDM1A 3708/4885HTR4 2537/4885ACKR3 2875/4885 |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | WEE1, WEE2, EGFR | KDM1A 3708/4885HTR4 2537/4885ACKR3 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.